Effect of erythropoietin levels on mortality in old age: The Leiden 85-plus study

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 18, 2010, Pages 1953-1958

  Den Elzen, Wendy P J ^a   Willems, Jorien M ^a   Westendorp, Rudi G J ^a,b   De Craen, Anton J M ^a   Blauw, Gerard Jan ^a,c   Ferrucci, Luigi ^d   Assendelft, Willem J J ^a   Gussekloo, Jacobijn ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Consortium for Healthy Ageing   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; COMORBIDITY; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; OXYGEN SATURATION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENESCENCE;

EID: 78650055354     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.100347     Document Type: Article

References (32)

1. Adamson JW, Longo DL. Anemia and polycythemia: introduction [chapter 58]. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison's principles of internal medicine. 17th ed. New York (NY): McGraw-Hill; 2008.
2. Krantz SB. Erythropoietin. Blood 1991;77:419-34.
3. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:449-89.
4. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864-77.
5. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74:468-73.
6. van der Meer P, Voors AA, Lipsic E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63-7.
7. George J, Patal S, Wexler D, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304-9.
8. Avkarogullari M, Bozkurt A, Akpinar O, et al. The relation between serum erythropoietin level and severity of disease and mortality in patients with chronic heart failure. Acta Cardiol 2008;63:297-302.
9. van der Meer P, Lok DJ, Januzzi JL, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008;29:1510-5.
10. Belonje AM, Westenbrink BD, Voors AA, et al. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan. Am Heart J 2009;157:91-6.
11. Belonje AM, Voors AA. van der Meer P, et al. Endogenous erythropoietin and outcome in heart failure. Circulation 2010;121:245-51.
12. der Wiel AB, van Exel E, de Craen AJ, et al. A high response is not essential to prevent selection bias: results from the Leiden 85-plus study. J Clin Epidemiol 2002;55:1119-25.
13. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968;405:5-37.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Bootsma-van der Wiel A, de Craen AJ, van Exel E, et al. Association between chronic diseases and disability in elderly subjects with low and high income: the Leiden 85-plus Study. Eur J Public Health 2005;15:494-7.
16. Heeren TJ, Lagaay AM, von Beek WC, et al. Reference values for the Mini-Mental State Examination (MMSE) in octo- and nonagenarians. J Am Geriatr Soc 1990;38:1093-6.
17. Winnicki M, Shamsuzzaman A, Lanfranchi P, et al. Erythropoietin and obstructive sleep apnea. Am J Hypertens 2004;17:783-6.
18. Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-7.
19. Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 2005;53:1360-5.
20. Price EA. Aging and erythropoiesis: current state of knowledge. Blood Cells Mol Dis 2008;41:158-65.
21. George J. Erythropoietin and outcome prediction in patients with heart failure: the plot thickens. Eur Heart J 2008;29:1481-2.
22. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005;118:1288.
23. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-32.
24. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-48.
25. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005;(3):CD003266.
26. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990;263:825-30.
27. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
28. Jones M, Schenkel B, Just J, et al. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis. Cancer 2004;101:1720-32.
29. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc 2007;55:1557-65.
30. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
31. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-8.
32. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-E71.